Alkyl amino acid derivatives useful as pharmaceutical agents
AssigneeWarner-Lambert Company
InventorsDavid Clive Blakemore, Justin Stephen Bryans, Sophie Caroline Williams
Life of this patent
Estimating the term…
Loading patent…
AssigneeWarner-Lambert Company
InventorsDavid Clive Blakemore, Justin Stephen Bryans, Sophie Caroline Williams
Estimating the term…
GABA-related pro-drugs of the formula (III) are provided that when administered to humans or other mammals provide an increased duration of active compound in the plasma compared to compounds of corresponding structure in which labile groups are not present. The compounds are of the formula (III) 1 In the above formula: P represents hydrogen or methyl; Q represents a labile amine- or amide-forming organic group that becomes removed in the human or animal body; R1 represents straight or branched C2-C6 alkyl, C3-C6 cycloalkyl or phenyl; R2 represents hydrogen or methyl; and R3 represents hydrogen, methyl or carboxyl; and R4 represents hydrogen or a labile ester-forming group selected from substituted and unsubstituted C1-C6 alkyl, benzyl and phenyl groups that become removed in the human or animal body. In the above formula when R1 is phenyl, R2, R3 and R4 are not simultaneously hydrogen. Pharmaceutically acceptable salts of any salt-forming compound within the above class are also included. The compounds may be used to treat a range of neurological conditions, e.g. epilepsy and pain.
A compound of the formula (III)
A compound selected from
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the formula (III)
Dependencies are inferred from the claim text.